Pharmacy Times
@pharmacytimes.bsky.social
Pharmacy Times® offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
Pinned
Hello BlueSky! Pharmacy Times® offers the latest news and insights for the #pharmacy professional and solutions that impact the everyday practice of pharmacy.
We are excited to share knowledge and connect with pharmacy professionals.
We are excited to share knowledge and connect with pharmacy professionals.
FDA's Oncologic Drugs Advisory Committee reviewed the sBLA for glofitamab + GemOx today. STARGLO trial showed a 41% OS benefit in transplant-ineligible R/R DLBCL, with implications for care delivery for pharmacists. FDA sBLA decision expected July 2025.
shorturl.at/J79IY
#OncologyPharmacy #DLBCL
shorturl.at/J79IY
#OncologyPharmacy #DLBCL
Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients
Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.
shorturl.at
May 20, 2025 at 7:37 PM
FDA's Oncologic Drugs Advisory Committee reviewed the sBLA for glofitamab + GemOx today. STARGLO trial showed a 41% OS benefit in transplant-ineligible R/R DLBCL, with implications for care delivery for pharmacists. FDA sBLA decision expected July 2025.
shorturl.at/J79IY
#OncologyPharmacy #DLBCL
shorturl.at/J79IY
#OncologyPharmacy #DLBCL
NCCN has released updates to breast cancer guidelines Version 4.2025 as of April 30, 2025. Changes include revised indications (olaparib, capecitabine) and new sequencing flexibility (taxane before anthracycline), as well as other updates.
#breastcancer #NCCN
shorturl.at/9yPPW
#breastcancer #NCCN
shorturl.at/9yPPW
NCCN Flash Update: Changes to NCCN Guidelines for Breast Cancer Version 4.2025
Updates on April 30, 2025, introduce changes to treatment regimens, sequencing flexibility, febrile neutropenia risk assessments, and drug-specific safety and supportive care guidance.
shorturl.at
April 30, 2025 at 9:28 PM
NCCN has released updates to breast cancer guidelines Version 4.2025 as of April 30, 2025. Changes include revised indications (olaparib, capecitabine) and new sequencing flexibility (taxane before anthracycline), as well as other updates.
#breastcancer #NCCN
shorturl.at/9yPPW
#breastcancer #NCCN
shorturl.at/9yPPW
NCCN’s 2025 Colon Cancer Guidelines now support DPYD genotyping before fluoropyrimidine chemotherapy.
Pharmacists are key to enacting this guideline through leading testing efforts and educating patients on their options.
shorturl.at/t3qT7
#Pharmacogenetics #DPYD #NCCN #PrecisionMedicine
Pharmacists are key to enacting this guideline through leading testing efforts and educating patients on their options.
shorturl.at/t3qT7
#Pharmacogenetics #DPYD #NCCN #PrecisionMedicine
NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025
NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy.
shorturl.at
April 25, 2025 at 9:34 PM
NCCN’s 2025 Colon Cancer Guidelines now support DPYD genotyping before fluoropyrimidine chemotherapy.
Pharmacists are key to enacting this guideline through leading testing efforts and educating patients on their options.
shorturl.at/t3qT7
#Pharmacogenetics #DPYD #NCCN #PrecisionMedicine
Pharmacists are key to enacting this guideline through leading testing efforts and educating patients on their options.
shorturl.at/t3qT7
#Pharmacogenetics #DPYD #NCCN #PrecisionMedicine
Call for submissions: Practice and Paradox
Pharmacy Practice in Focus: Oncology is looking for submissions to our Practice and Paradox column—where we explore the tension between the calling of health care and the system-level and financial realities of the field.
#OncologyPharmacy
Pharmacy Practice in Focus: Oncology is looking for submissions to our Practice and Paradox column—where we explore the tension between the calling of health care and the system-level and financial realities of the field.
#OncologyPharmacy
April 23, 2025 at 9:42 PM
Call for submissions: Practice and Paradox
Pharmacy Practice in Focus: Oncology is looking for submissions to our Practice and Paradox column—where we explore the tension between the calling of health care and the system-level and financial realities of the field.
#OncologyPharmacy
Pharmacy Practice in Focus: Oncology is looking for submissions to our Practice and Paradox column—where we explore the tension between the calling of health care and the system-level and financial realities of the field.
#OncologyPharmacy
NCCN has updated Version 3.2025 of their EEJC guidelines for squamous cell carcinoma.
Tislelizumab-based combos (with oxaliplatin or cisplatin + paclitaxel) are now preferred first-line options for PD-L1 CPS ≥1. New dosing schedules as well.
#Oncology #NCCN #SCC
shorturl.at/O4c6o
Tislelizumab-based combos (with oxaliplatin or cisplatin + paclitaxel) are now preferred first-line options for PD-L1 CPS ≥1. New dosing schedules as well.
#Oncology #NCCN #SCC
shorturl.at/O4c6o
NCCN Flash Update: Guideline Update for Esophageal and Esophagogastric Junction Cancers in Version 3.2025
The Version 3.2025 update adds tislelizumab-based regimens as preferred first-line treatments and introduces new dosing schedules for PD-L1–positive esophageal squamous cell carcinoma.
shorturl.at
April 23, 2025 at 6:00 PM
NCCN has updated Version 3.2025 of their EEJC guidelines for squamous cell carcinoma.
Tislelizumab-based combos (with oxaliplatin or cisplatin + paclitaxel) are now preferred first-line options for PD-L1 CPS ≥1. New dosing schedules as well.
#Oncology #NCCN #SCC
shorturl.at/O4c6o
Tislelizumab-based combos (with oxaliplatin or cisplatin + paclitaxel) are now preferred first-line options for PD-L1 CPS ≥1. New dosing schedules as well.
#Oncology #NCCN #SCC
shorturl.at/O4c6o
In older postmenopausal women, leukocyte count was found to be an independent predictor of long #COVID symptom severity, highlighting its potential for use as a novel symptom biomarker.
Learn more: bit.ly/43x8SED
Learn more: bit.ly/43x8SED
New Research Sheds Light on Link Between Leukocyte Count and Long COVID Symptom Severity
In older postmenopausal women, leukocyte count was found to be an independent predictor of long COVID symptom severity, highlighting its potential for use as a novel symptom biomarker.
bit.ly
March 10, 2025 at 8:20 PM
In older postmenopausal women, leukocyte count was found to be an independent predictor of long #COVID symptom severity, highlighting its potential for use as a novel symptom biomarker.
Learn more: bit.ly/43x8SED
Learn more: bit.ly/43x8SED
#BREAKING: The #FDA has approved tenecteplase (TNKase; Genentech), a thrombolytic or clot-dissolving agent, for the treatment of adult patients with acute ischemic stroke — marking tenecteplase as the first #stroke medicine to be approved by the FDA in nearly 30 years.
Learn more: bit.ly/4bxdEUH
Learn more: bit.ly/4bxdEUH
Tenecteplase Receives FDA Approval, Marking First New Stroke Medication in Nearly 30 Years
In a clinical trial, tenecteplase was shown to be a comparable alternative to alteplase.
bit.ly
March 3, 2025 at 9:22 PM
#BREAKING: The #FDA has approved tenecteplase (TNKase; Genentech), a thrombolytic or clot-dissolving agent, for the treatment of adult patients with acute ischemic stroke — marking tenecteplase as the first #stroke medicine to be approved by the FDA in nearly 30 years.
Learn more: bit.ly/4bxdEUH
Learn more: bit.ly/4bxdEUH
The #FDA has approved label changes for buprenorphine extended-release injection, including alternative injection sites and a rapid initiation protocol, which stand as a major achievement in the treatment of patients with moderate to severe #opioid use disorder.
Learn more: bit.ly/4kgPT7q
Learn more: bit.ly/4kgPT7q
FDA OKs Label Changes for Buprenorphine Injections, Reducing Time to Treatment in Opioid Use Disorder
The label changes to buprenorphine extended-release injections can increase convenience and adherence for patients with moderate to severe opioid use disorder.
bit.ly
February 25, 2025 at 8:51 PM
The #FDA has approved label changes for buprenorphine extended-release injection, including alternative injection sites and a rapid initiation protocol, which stand as a major achievement in the treatment of patients with moderate to severe #opioid use disorder.
Learn more: bit.ly/4kgPT7q
Learn more: bit.ly/4kgPT7q
A next-generation molecular #COVID/#Flu multiplex test (Metrix; Aptitude Medical Systems, Inc) received emergency use authorization from the #FDA for detection of SARS-CoV-2, Influenza A virus, and Influenza B virus in 20 minutes.
Learn more: bit.ly/4i9sR0j
Learn more: bit.ly/4i9sR0j
Molecular COVID/Flu Multiplex Test is Granted FDA Emergency Use Authorization
The test results are available in as little as 20 minutes.
bit.ly
February 24, 2025 at 9:51 PM
A next-generation molecular #COVID/#Flu multiplex test (Metrix; Aptitude Medical Systems, Inc) received emergency use authorization from the #FDA for detection of SARS-CoV-2, Influenza A virus, and Influenza B virus in 20 minutes.
Learn more: bit.ly/4i9sR0j
Learn more: bit.ly/4i9sR0j
Reposted by Pharmacy Times
AKF Chief Medical Officer @pranavgarimella.bsky.social sat down with @pharmacytimes.bsky.social to discuss the recent FDA approval of semaglutide to reduce kidney disease & cardiovascular death risks in adults with type 2 diabetes & chronic kidney disease. Watch the interview: bit.ly/41sSynb
Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes
Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.
www.pharmacytimes.com
February 21, 2025 at 4:11 PM
AKF Chief Medical Officer @pranavgarimella.bsky.social sat down with @pharmacytimes.bsky.social to discuss the recent FDA approval of semaglutide to reduce kidney disease & cardiovascular death risks in adults with type 2 diabetes & chronic kidney disease. Watch the interview: bit.ly/41sSynb
There have been 68 confirmed human cases of #H5N1 reported by the CDC as of February 14, 2025; however, a recent study published by the agency suggests that this number is an undercount because of asymptomatic illness.
Learn more: bit.ly/4gO3ss7
Learn more: bit.ly/4gO3ss7
CDC Study Raises Concerns Over Undetected H5N1 Infections in Humans
Research suggests H5N1 may be spreading undetected among humans, particularly in veterinarians with frequent animal exposure.
bit.ly
February 18, 2025 at 9:27 PM
There have been 68 confirmed human cases of #H5N1 reported by the CDC as of February 14, 2025; however, a recent study published by the agency suggests that this number is an undercount because of asymptomatic illness.
Learn more: bit.ly/4gO3ss7
Learn more: bit.ly/4gO3ss7
#Drugshortages are multifaceted, involving manufacturers, regulatory agencies, and health care providers, in a collaborative effort to identify and mitigate issues. All stakeholders should work together to determine and address drug shortages.
Learn more: bit.ly/4k6fbEW
Learn more: bit.ly/4k6fbEW
Because Ned Said: Drug Shortage or Not, That Is the Question
All stakeholders should work together to determine and address drug shortages.
bit.ly
February 18, 2025 at 4:44 PM
#Drugshortages are multifaceted, involving manufacturers, regulatory agencies, and health care providers, in a collaborative effort to identify and mitigate issues. All stakeholders should work together to determine and address drug shortages.
Learn more: bit.ly/4k6fbEW
Learn more: bit.ly/4k6fbEW
#BREAKING: Chikungunya vaccine (VimKunya; Bavarian Nordic A/S) was granted #FDA approval for patients aged 12 and older to prevent against #chikungunya virus (CHIKV) during travel.
Learn more: bit.ly/3X3k0VG
Learn more: bit.ly/3X3k0VG
Chikungunya Vaccine Receives FDA Approval for Individuals Ages 12 and Older
The approval makes the vaccine the first of its kind for this indication in the United States.
bit.ly
February 17, 2025 at 9:13 PM
#BREAKING: Chikungunya vaccine (VimKunya; Bavarian Nordic A/S) was granted #FDA approval for patients aged 12 and older to prevent against #chikungunya virus (CHIKV) during travel.
Learn more: bit.ly/3X3k0VG
Learn more: bit.ly/3X3k0VG
RxPass, #Amazon Pharmacy’s subscription service for common medications, has demonstrated significant improvements in medication adherence and out-of-pocket cost reductions — making it difficult for retail pharmacies to compete with Amazon Pharmacy’s business model.
Learn more: bit.ly/3EyHlIx
Learn more: bit.ly/3EyHlIx
Amazon's RxPass Shown to Improve Days' Supply, Refills, and Out-of-Pocket Costs for Common Medications
Amazon Pharmacy’s subscription service could cause sale disruptions for traditional retail pharmacies.
bit.ly
February 11, 2025 at 8:42 PM
RxPass, #Amazon Pharmacy’s subscription service for common medications, has demonstrated significant improvements in medication adherence and out-of-pocket cost reductions — making it difficult for retail pharmacies to compete with Amazon Pharmacy’s business model.
Learn more: bit.ly/3EyHlIx
Learn more: bit.ly/3EyHlIx
Mindfulness training groups could be recommended for those who have residual #opioid cravings and are receiving maintenance therapy with buprenorphine.
Learn more: bit.ly/4jRsN7g
Learn more: bit.ly/4jRsN7g
Mindfulness Program Reduces Opioid Cravings During Buprenorphine Treatment
There were no substantial differences for the mindfulness with substance use or anxiety outcomes compared with the recovery control group.
bit.ly
February 10, 2025 at 8:46 PM
Mindfulness training groups could be recommended for those who have residual #opioid cravings and are receiving maintenance therapy with buprenorphine.
Learn more: bit.ly/4jRsN7g
Learn more: bit.ly/4jRsN7g
The demands of the #pharmacy profession—long hours, high stress, and emotional strain—can take a toll on pharmacists’ well-being. To sustain their ability to care for others, pharmacists must also care for themselves.
Read more: bit.ly/3WOi2sl
Read more: bit.ly/3WOi2sl
Caring for the Caregiver: Prioritizing Well-Being as a Pharmacist
The demands of the pharmacy profession—long hours, high stress, and emotional strain—can take a toll on pharmacists’ well-being.
bit.ly
February 6, 2025 at 8:35 PM
The demands of the #pharmacy profession—long hours, high stress, and emotional strain—can take a toll on pharmacists’ well-being. To sustain their ability to care for others, pharmacists must also care for themselves.
Read more: bit.ly/3WOi2sl
Read more: bit.ly/3WOi2sl
Major #FDA news: Ranibizumab injection (Susvimo; Roche) 100 mg/mL administered through a port delivery platform (PDP) became the first and only FDA-approved continuous treatment to maintain vision in patients with #diabetic macular edema.
Learn more: bit.ly/4gsyaqf
Learn more: bit.ly/4gsyaqf
Ranibizumab Injection Delivered Through Port Delivery Platform Is FDA Approved as Continuous Delivery Treatment for DME
Diabetic macular edema (DME) is the leading cause of new blindness in the US.
bit.ly
February 5, 2025 at 6:41 PM
Major #FDA news: Ranibizumab injection (Susvimo; Roche) 100 mg/mL administered through a port delivery platform (PDP) became the first and only FDA-approved continuous treatment to maintain vision in patients with #diabetic macular edema.
Learn more: bit.ly/4gsyaqf
Learn more: bit.ly/4gsyaqf
February 4th is World Cancer Day, a global initiative aimed at raising awareness, reducing stigma, and promoting equitable access to #cancer care, with pharmacy professionals playing a vital role in prevention, treatment, and support for patients and communities.
Learn more: bit.ly/411O1Yw
Learn more: bit.ly/411O1Yw
World Cancer Day: A Call to Action
World Cancer Day, observed annually on February 4th, is a global initiative aimed at raising awareness, reducing stigma, and promoting equitable access to cancer care, with pharmacy professionals play...
bit.ly
February 4, 2025 at 7:06 PM
February 4th is World Cancer Day, a global initiative aimed at raising awareness, reducing stigma, and promoting equitable access to #cancer care, with pharmacy professionals playing a vital role in prevention, treatment, and support for patients and communities.
Learn more: bit.ly/411O1Yw
Learn more: bit.ly/411O1Yw
Hello BlueSky! Pharmacy Times® offers the latest news and insights for the #pharmacy professional and solutions that impact the everyday practice of pharmacy.
We are excited to share knowledge and connect with pharmacy professionals.
We are excited to share knowledge and connect with pharmacy professionals.
February 3, 2025 at 9:53 PM
Hello BlueSky! Pharmacy Times® offers the latest news and insights for the #pharmacy professional and solutions that impact the everyday practice of pharmacy.
We are excited to share knowledge and connect with pharmacy professionals.
We are excited to share knowledge and connect with pharmacy professionals.